Refund for unused/expired funded influenza vaccine
One refund will be available for a total of 10 doses of unused INFLUVAC® TETRA and/or one dose of unused FLUARIX® TETRA and/or 10 doses of unused INFLUVAC® from any one account. To be eligible for a refund, the unused stock must be returned prior to 31 January 2019. Please ensure you continue to have influenza vaccine stock available until 31 December for those who are eligible for influenza vaccination.
Contact Healthcare Logistics on 0508 425 358 to request a Return Authorisation.
INFLUVAC® (trivalent influenza vaccine) overview – *NEW* fact sheet 3 July 2018
2018 Vaccine order form – Updated 2 August 2018
Funded influenza vaccines for 2018:
INFLUVAC® TETRA (quadrivalent)
For adults and children aged 3 years or older.
FLUARIX® TETRA (quadrivalent) *OUT OF STOCK*
INFLUVAC® (trivalent) *REPLACES FLUARIX TETRA*
For children aged under 3 years, i.e. 6–35 months.
IMPORTANT NOTE: INFLUVAC® and INFLUVAC® TETRA packaging is very similar. Spot the package differences when you select influenza vaccine from the fridge and check the syringe label before you vaccinate.
INFLUVAC® dose for children aged under 3 years, i.e. 6–35 months, is a half dose of 0.25 mL
The three influenza strains included in both the trivalent and quadrivalent vaccines are:
• A/Michigan/45/2015 (H1N1) pdm09- like virus
• A/Singapore/INFIMH-16-0019/2016 (H3N2)-like virus
• B/Phuket/3073/2013-like virus
The additional influenza strain included in the quadrivalent vaccines is:
• B/Brisbane/60/2008-like virus
Minimum order requirements
The total influenza vaccine order must meet minimum quantities as follows:
|Min 60 doses
||Min 60 doses
||Min 60 doses
||Min 30 doses
||Min 20 doses
||Min 10 doses
New influenza vaccination precaution
Influenza vaccination may be contraindicated or need to be delayed for people receiving any of the following four new cancer treatments:
- atezolizumab (Tecentriq®),
- ipilimumab (Yervoy®),
- nivolumab (Opdivo®)
- pembrolizumab (Keytruda®)
These are the only four cancer treatements in New Zealand that require influenza vaccination to be delayed.
The immune-stimulant actions of these treatments on the immune system increase a person’s risk of developing autoimmune conditions.
It is not known whether receipt of an influenza vaccine whilst receiving these treatments or for up to six months after treatment increases a theoretical risk of triggering the
occurrence of these side effects.
Please contact the person’s oncologist or 0800 IMMUNE (0800 466 863) for current advice about influenza vaccination for these people BEFORE administering the vaccine.
(page 16 in the Flu kit)
Vaccine comparison chart – Updated 1 July 2018
References for 2018 Influenza Kit